Definitive collection of precision medicine technology and diagnostic solutions

AVENIO ctDNA Surveillance Kits (Roche)

The AVENIO ctDNA Surveillance Kit is an NGS liquid biopsy assay that is specially designed to enable researchers to monitor tumor burden in lung and colorectal cancer over time, as well as to assess for minimal residual disease (MRD). This assay contains 471 frequently mutated regions associated with the presence of disease across 197 genes, including those in the U.S. National Comprehensive Cancer Network (NCCN) Guidelines.1

Roche Sequencing and Life Science

9115 Hague Road
Indianapolis, IN 46256

Learn more about this product

REQUEST INFO: AVENIO ctDNA Surveillance Kits (Roche)


  • Confidently report all four mutation classes: SNVs, indels, fusions, and CNVs.
  • Delivers exceptional analytical performance supported by integrated digital error suppression (iDES) strategies, combining molecular barcodes with in silico error suppression techniques.2,3
  • Uses an intelligent algorithm that applies population-scale data from multiple cancer databases to design a panel with broad research subject coverage.3
  • Enables researchers to detect mutations derived from a variety of solid tumor indications using a single, streamlined workflow.†
  • Maximizes the number of mutations detected per tumor while minimizing the panel size, enabling researchers to use the combined power of multiple mutations to increase the detection of ctDNA several fold while minimizing sequencing costs.

Research focus

  • Primary: Lung, Colorectal
  • Secondary: Breast, Gastric, Prostate, Glioma, Melanoma, Ovarian, Thyroid, and Pancreatic


  • Non-invasive tumor profiling
  • Non-invasive detection of resistance biomarkers
  • Non-invasive serial tumor burden monitoring
  • Non-invasive detection of minimal residual disease
1.  National Comprehensive Cancer Network. October 15, 2016.
2.  Newman AM, Lovejoy AF, Klass DM, et al. Integrated digital error suppression for improved detection of circulating tumor DNA. Nature Biotechnology. 2016;34(5):547–555. doi:10.1038/nbt.3520.
3.  Newman AM, Bratman SV, To J, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nature Medicine. 2014;20(5):548–554. doi:10.1038/nm.3519.
†   Required hardware: Illumina NextSeq 500/550 sequencer and Roche Oncology Analysis Server. NextSeq 500/550 instruments and associated sequencing reagents are manufactured and sold by lllumina and are not supplied by Roche

For Research Use Only. Not for use in diagnostic procedures.
AVENIO is a trademark of Roche. NEXTSEQ is a trademark of Illumina. All other product names and trademarks are the property of their respective owners.
© 2020 Roche Sequencing & Life Science. All rights reserved.

Posters & Papers

Webinars & Videos

AVENIO ctDNA Surveillance Kits from Roche

AVENIO ctDNA Surveillance Kits (Roche)

Scroll Up